Elevation Oncology, Inc. (ELEV) |
|
1.51 0.02 (1.34%)
|
06-26 23:04 |
|
Open: |
1.44 |
Pre. Close: |
1.49 |
|
High:
|
1.579 |
Low:
|
1.43 |
|
Volume:
|
287,803 |
Market Cap:
|
35(M) |
|
|
|
|
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.58 - 1.58 |
1.58 - 1.59 |
|
Low:
|
1.42 - 1.42 |
1.42 - 1.43 |
|
Close:
|
1.5 - 1.51 |
1.51 - 1.52 |
|
Technical analysis |
as of: 2022-06-24 4:39:32 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 3.86 One year: 5.38 |
| Support: |
Support1: 1.2 Support2: 0.99 |
| Resistance: |
Resistance1: 3.3 Resistance2: 4.61 |
| Pivot: |
1.62  |
| Moving Average: |
MA(5): 1.42  MA(20): 1.8
MA(100): 2.82 MA(250): 6.11 |
| MACD: |
MACD(12,26): -0.4 Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 24.8 %D(3): 19.5 |
| RSI: |
RSI(14): 34.5 |
| 52-week: |
High: 16.21 Low: 1.2 |
| Average Vol(K): |
3-Month: 668 (K) 10-Days: 496 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ELEV ] has closed above bottom band by 41.8%. Bollinger Bands are 1.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Sun, 26 Jun 2022
Hollifield: Elevator rides have their ups and downs - Winston-Salem Journal
Sun, 26 Jun 2022
‘Lift Us Up’ campaign to support elevator at Kingston’s Circle of Friends for the Dying home - The Daily Freeman
Sun, 26 Jun 2022
Willoughby: Elevation, ore and exhausted miners | AspenTimes.com - The Aspen Times
Thu, 23 Jun 2022
Memorial fund to benefit family of grain elevator victim - WHBF - OurQuadCities.com
Wed, 22 Jun 2022
Activists seize City Hall elevators, demand SRO elevator repairs - Mission Local
Wed, 22 Jun 2022
AEW “Dark: Elevation” Spoilers for 6/27/2022 - Wrestling Headlines
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
23 (M) |
| Shares Float |
8 (M) |
|
% Held by Insiders
|
2.3 (%) |
|
% Held by Institutions
|
93.7 (%) |
|
Shares Short
|
937 (K) |
|
Shares Short P.Month
|
770 (K) |
Stock Financials |
|
EPS
|
-2.5 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
5.32 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-26.9 |
|
Return on Equity (ttm)
|
-45.9 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.91 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-35 (M) |
|
Levered Free Cash Flow
|
-19 (M) |
Stock Valuations |
|
PE Ratio
|
-0.61 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.28 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.02 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
